在Abemaciclib诱导的肝损伤中特征性肝缩:对三个病例的比较审查
Yuwa Ando1, Tsunamasa Watanabe1, Tatsuya Suzuki1
1Department of Gastroenterology, St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan.
概括
在乳腺癌患者中,Abemaciclib可能会导致快速肝缩和肝损伤. 肝缩和奇莱迪蒂综合征的成像发现是这种药物诱导的肝损伤的关键指标.
科学领域:
- 肝病学 肝病学是一种肝病学.
- 在瘤学瘤学.
- 放射学 放射学是指放射学
背景情况:
- 阿贝马西克利布是激素受体阳性,HER2阴性乳腺癌的标准治疗方法.
- 阿贝马西克利布可以诱导肝功能障碍,这是一个重要的临床问题.
研究的目的:
- 报告药物诱导性肝损伤 (DILI) 的第一个病例从abemaciclib.
- 为了突出在abemaciclib诱导的肝损伤中快速发病的肝缩的特征性成像发现.
主要方法:
- 对三名乳腺癌患者的回顾性分析,这些患者在开始abemaciclib.lib后出现肝功能障碍.
- 对临床数据和对比度增强CT (CECT) 扫描进行审查,以确定成像特征.
- 影像检测结果与临床结果和治疗反应的相关性.
主要成果:
- 在CECT扫描中,三例由abemaciclib诱导的肝损伤呈现出特征性肝缩和Chilaiditi综合征.
- 患者在开始服用abemaciclib的两个月内出现肝功能障碍或急性肝衰竭.
- 结果各不相同,一些患者经历了治疗的改善,而另一些患者则面临疾病进展或肝衰竭.
结论:
- 这份报告是第一个描述了与abemaciclib诱导的肝损伤相关的快速发作的肝缩的成像特征.
- 识别这些成像特征可能有助于区分abemaciclib诱导的肝损伤与肝功能障碍的其他原因.
- 需要进一步的研究,以了解该机制,并优化管理abemaciclib诱导的肝损伤.
相关概念视频
01:26Diseases of the Liver and Gallbladder
Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not related to...
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not related to...
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
01:14Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug
In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
01:08Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
01:23Cirrhosis I: Introduction
Cirrhosis is a chronic, irreversible liver disease characterized by the widespread replacement of healthy liver tissue with fibrotic scar tissue and the formation of regenerative nodules.Etiology of cirrhosisCirrhosis results from sustained liver injury that triggers progressive fibrosis and structural remodeling. The underlying causes are diverse, encompassing common and less frequent clinical conditions. Regardless of the origin, all causes lead to chronic inflammation, hepatocyte loss, and...